World Aids Day, 2019!

world-aids-day-.jpg

Bentham Science Publish articles related to WORLD AIDS DAY in its subscription based journals including: 

 

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Volume 5, Issue 1, February, 2006 – Volume 18, Issue 2, September, 2019


Current HIV Research
Volume 1, Issue 1, January, 2003 – Volume 17, Issue 5, September, 2019


Current Immunology Reviews
Volume 1, Issue 1, January, 2005 – Volume 15, Issue 2, August, 2019

 

Endocrine, Metabolic & Immune Disorders – Drug Targets
Volume 6, Issue 1, March, 2006 – Volume 19, Issue 8, December, 2019


Recent Patents on Inflammation & Allergy Drug Discovery
Volume 1, Issue 1, February, 2007 – Volume 13, Issue 2, October, 2019

For eBooks, Please find the link HERE consisting of all the relevant eBooks and avail 30% DISCOUNT OFFER on related Books!

 

 

New Issues of various Bentham Science Journals

 

1. Cardiovascular & Hematological Agents in Medicinal Chemistry, Vol: 16, Issue:1

https://bit.ly/2AWUnwp

2. Letters in Organic Chemistry, Vol: 15, Issue: 10

https://bit.ly/2QCmhCY

3. Current Vascular Pharmacology, Vol: 16, Issue: 6

https://bit.ly/2AVbmiI

4. Current Pharmaceutical Design, Vol: 24, Issue: 17

https://bit.ly/2PSKAzs

5. Recent Patents on Inflammation & Allergy Drug Discovery, Vol: 12, Issue: 2

https://bit.ly/2QrcEqY

6. Current Organic Chemistry, Vol: 22, Issue: 15

https://bit.ly/2SXAnAH

7. Current Pharmaceutical Design, Vol: 24, Issue: 18

https://bit.ly/2PK2qF3

8. Recent Patents on Biotechnology, Vol: 12, Issue: 3

https://bit.ly/2z29KlC

9. Mini-Reviews in Medicinal Chemistry, Vol: 18, Issue: 16

https://bit.ly/2qCXROI

 

 

Issues.jpg

RECENTLY PUBLISHED ISSUES – BENTHAM SCIENCE JOURNALS

Recent Patents on Inflammation & Allergy Drug Discovery 11-2

http://bit.ly/2C7S8si

Current Rheumatology Reviews 13-3

http://bit.ly/2lou1KD

Current Bioinformatics 12-6

http://bit.ly/2EbgFds

Current Drug Metabolism 18-9

http://bit.ly/2C72usv

Current Stem Cell Research & Therapy 13-1

http://bit.ly/2lp9Bky

Current Organic Chemistry 21-25

http://bit.ly/2CfRqIO

Current Smart Materials 2-2

http://bit.ly/2DsWNRJ

recent-issues

WISHING A VERY HAPPY BIRTHDAY TO DR. KHURSHID ZAMAN!

Dr khurshid zaman

DR. KHURSHID ZAMAN

EDITOR-IN-CHIEF: Recent Patents on Anti-Cancer Drug DiscoveryRecent Patents on Inflammation & Allergy Drug Discovery & Recent Patents on Mechanical Engineering

Bentham Science Publishers
USA

Press Release – Flavonoid derivatives targeting NF-kappaB

Research Article: Cytotoxicity and Anti-inflammatory Activity of Flavonoid Derivatives Targeting NF-kappaB

The aim of the study was to develop new synthetic anti-inflammatory and cytotoxic agents targeting NF-kappaB

Nuclear factor-kappaB (NF-kappaB) has been reported to regulate various genes involved in cancer and inflammation. Accordingly, drugs inhibiting NF-kappaB may possess both anti-inflammatory and anticancer properties. So there is a need to discover novel compounds which should not only be a potential lead but also less toxic and cost effective. In the view of this strategy, three series of flavanone derivatives (30 compounds in total) were synthesized followed by the characterization and establishment of the structure using various spectroscopic methods viz. UV, IR H1NMR, C13NMR and mass spectrometry. All 30 synthesized compounds were evaluated for anti-inflammatory and cytotoxic activity. In vivo anti-inflammatory activity of flavanone derivatives based on carrageenan-induced rat paw edema model identified compounds such as (10b), (1c) and (2c) as potent anti-inflammatory agent, whereas the compounds (10b), (6b), (4b), (2b), (6a), (4a), (5c) and (3c) have shown promising cytotoxicity against different cancer cell lines ( MCF-7, HeLa, COLO-205 and PC-3 cancer cell lines). Among the synthesized flavanone derivative, compounds (10b) and (4b) exhibited the maximum cytotoxic effect against different cancer cell lines. Furthermore, all the compounds were docked into the active site of NF-kappaB receptor to identify the most potential candidates. The top ranked compounds (10b, 4b) were subjected to cell cycle analysis using flow cytometer and have shown to induce cell cycle arrest mainly at G2/M phase. Promising activity of the compounds (10b) and (4b) demands further in vivo anti-cancer activity and clinical studies. Excellent correlation was observed between docking score and cytotoxic activity/anti-inflammatory potency of screened drugs. Docking studies revealed that carbonyl oxygen, NO2, OH, and OCH3 of the flavanone derivatives were involved in hydrogen bonding with various amino acids of the receptor. This confirms our hypothesis that conjugation of two pharmacophores might improve the pharmacological profile of synthesized compounds.

For more information, visit: http://www.eurekaselect.com/147366

Bentham Press Release!

Bentham Science Journals indexed in The Emerging Sources Citation Index (ESCI) by Thomson Reuters

The Emerging Sources Citation Index (ESCI) has accepted to index two journals published by Bentham Science Publishers. The titles are: Recent Patents on Inflammation & Allergy Drug Discovery and Recent Patents on Endocrine, Metabolic & Immune Drug Discovery.

The Emerging Sources Citation Index (ESCI) is a new index launched by Thomson Reuters, extending the universe of publications in Web of Science to include high-quality, peer-reviewed publications of regional importance and in emerging scientific fields.

Recent Patents on Inflammation & Allergy Drug Discovery and Recent Patents on Endocrine, Metabolic & Immune Drug Discovery are published by Bentham Science under the banner of ‘Patent Review titles’. The journals publish peer-reviewed review and research articles on important recent patents on these topics.

Article by Disease – “Role of Galectins in Allergic Disorders”

Article by Disease on “Allergy”

Abstract:

Background: Allergen avoidance, pharmacotherapy; with antihistamines, anti-leukotrienes, corticosteroids and bronchodilatorsas well as monoclonal antibodies; and allergen specific immunotherapy stand as confirmed approaches for the management of allergic disorders as asthma, allergic rhinitis/rhinoconjunctivitis, atopic dermatitis, food allergies and anaphylaxis. Galectins are members of animal lectin protein family, with binding specificity for β-galactoside sugars. These highly conserved proteins are known to be expressed in various effector cells of the immune system, exert immuno-regulatory activities, and enroll in tissue inflammation and regulation of immune homeostasis.

Objective: This review aims to explain the galectin family and influence of galectins in the immune mechanisms of allergic disorders.

Results: Galectins have multiple roles in innate and adaptive immunity. Intense research in the field of immunology related with galectins have given rise to several patent applications. Those, increasing in vivo efficacy of galectins for therapeutic applications, utilizing galectins for immune stimulation and prolongation of immune responses, utilization of them as disease markers are pioneers. As immune cells can be targeted by galectins, cells containing these molecules can be used for immune intervention. Regulation of cytokine productions by immune cells as IL-1β and IL-10 as well as dendritic cell functions by galectins may be efficient in limitation of some immune-mediated disorders.

Conclusion: Taken all together, better learning of galectin biology together with detailed revealing of galectin-immune system interactions have great potential for immune interventions targeting allergy-related disorders.

Read more: http://benthamscience.com/journals/recent-patents-on-inflammation-and-allergy-drug-discovery/volume/10/issue/1/page/2/

Article By Disease: Allergy

New Patents of Fixed Combinations of Nasal Antihistamines and Corticosteroids in Allergic Rhinitis

Author(s): Ole D. Wolthers

 

Abstract: During the last few years, fixed combinations of intranasal antihistamines and corticosteroids have been introduced for treatment of allergic rhinitis. The aim of this systematic review was to assess recent patents and clinical evidence for fixed combinations of intranasal antihistamines and intranasal corticosteroids in allergic rhinitis. Data base searches revealed that intranasal combinations of the antihistamine azelastine with the corticosteroids mometasone furoate, ciclesonide and fluticasone propionate, respectively, have been patented. Four randomized, double-blinded, parallelgroup, placebo-controlled, multicenter trials sponsored by the manufacturer evaluated the fixed combination of intranasal azelastine 125µg and fluticasone propionate 50µg administered as one dose per nostril b.i.d. in patients with moderate-tosevere symptomatic allergic rhinitis ≥ 12 years of age. Three of the studies were published as a meta-analysis which found the fixed combination of azelastine and fluticasone propionate statistically significantly more efficacious in reducing baseline total nasal symptom score by 5.7 as compared to azelastine (4.4; P < 0.001), fluticasone propionate (5.1; P < 0.001) and placebo (3.0; P < 0.001). The findings were supported by secondary assessments of scores of specific nasal and ocular symptoms.

Download the complete article from here: http://www.eurekaselect.com/node/114548/article


 

This article is from the journal Recent Patents on Inflammation & Allergy Drug Discovery 

 

Recently Published Issue of The Journal: Recent Patents on Inflammation & Allergy Drug Discovery

Recent Patents on Inflammation & Allergy Drug Discovery publishes review and research articles, and guest edited thematic issues on recent patents in the field of inflammation and allergy drug discovery e.g. on novel bioactive compounds, analogs and targets. A selection of important and recent patents in the field is also included in the journal. The journal is essential reading for all researchers involved in inflammation and allergy drug design and discovery. The journal also covers recent research (where patents have been registered) in fast emerging therapeutic areas/targets & therapeutic agents related to inflammation and allergy drug discovery.

Following are the articles recently published in the journal Recent Patents on Inflammation & Allergy Drug Discovery, 08 Issue 03:

Article: Exocrine Pancreas Involvement in Celiac Disease: A Review
Author(s): Raffaele Pezzilli

Article: Advances of Knowledge on Allergic Inflammation and the Oral Mucosa
Author(s): Cristoforo Incorvaia, Nicola Fuiano, Franco Frati and Francesco Marcucci

Article: Unusual Food Allergy: AlioideaAllergic Reactions Overview
Author(s): Carmen Cantisani, Bianca Visconti, Giovanni Paolino, Federica Frascani, Sonia Tofani, Gilda Fazia and Stefano Calvieri

Article: Hepatic Encephalopathy: Cause and Possible Management with Botanicals Author(s): Suyash Tripathi and Yamini B. Tripathi

Article: Glaucoma Eye Drops Adverse Skin Reactions
Author(s): Carmen Cantisani, Marina Ambrifi, Federica Frascani, Gilda Fazia, Giovanni Paolino, Roberto Lisi and Stefano Calvieri

Article: Prospective Trial of an Herbal Formula BYSH and Saw Palmetto in Patients with Hormonal Refractory Prostate Cancer: A Pilot Study
Author(s): Anthony C.-F. Ng, K.-F. Cheng and P.-C. Leung

Article: Investigation of Gene Expression Pattern of 5HTR2a and MAO-A in PBMCs of Individuals Who Had Been Exposed to Air Pollution in Highly Polluted Area
Author(s): Hajar Sheikhha, Somayeh Emadi, Saman Jorbozedar, Gholamreza D. Deilami and Ghasem Ahangari

Article: Minocycline as Add-On Treatment Decreases the Negative Symptoms of Schizophrenia; A Randomized Placebo-Controlled Clinical Trial
Author(s): Ahmad Ghanizadeh, Sara Dehbozorgi, Motahhar OmraniSigaroodi and Zahra Rezaei

Article: The Role of Chlamydia pneumoniae in the Etiology of Keratoconjunctivitis Sicca (KCS)
Author(s): Jan Krasny, Dana Hruba and Magdalena Netukova

For more details, please visit: http://bit.ly/13WVxEN

 

%d bloggers like this: